Search Results
Sep 10, 2026, 09:30 ET HealthWell Foundation Announces Panel Session at the NASP inSPire 2026 Specialty Pharmacy Conference
Era of Legislative Shifts – Wednesday, September 23, 2026, 10:00 AM - 10:50 AM EST.Recent health care legislation is reshaping prescription drug affordability, insurance coverage, and access to specialty medications. The Inflation Reduction Act introduced significant Medicare Part D changes,
More news about: HealthWell Foundation
Sep 10, 2026, 09:07 ET Lil' Drug Store Products Acquires Navajo's Health, Beauty and Wellness Portfolio
Grocery and Drug, Expanding Consumer Access to Trial and Travel ProductsCEDAR RAPIDS, Iowa, Sept. 10, 2026 /PRNewswire/ -- Lil' Drug Store Products,
More news about: Lil’ Drug Store
Sep 10, 2026, 09:06 ET New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States
NCCN.org/drug-shortages.When asked if national or state policies have made the issue of drug shortages better or worse since 2023, 4% of pharmacy directors surveyed said it has gotten
More news about: National Comprehensive Cancer Network
Sep 10, 2026, 09:05 ET Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
older adults about COVID-19 and NUVAXOVID (COVID-19 Vaccine, Adjuvanted), the only protein-based, non-mRNA COVID-19 vaccine approved by the US Food and Drug Administration (FDA). "Serve Up Protection" aims to reach people during the respiratory season on and off the court using multimedia education, trusted
More news about: USA Pickleball
Sep 10, 2026, 09:00 ET NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense will deliver a corporate presentation highlighting the Company's recent clinical and regulatory progress with PrimeC, its lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), including preparations for the Phase 3 PARAGON trial and the Company's strategy
More news about: NeuroSense
Sep 10, 2026, 09:00 ET DeepIntent Launches Cora, the First Fully Agentic Marketing Platform for Healthcare
60% of drug treatments fail to meet their forecasted commercial goals, underscoring the difficulty of developing a clear path to commercial success. As pharma
More news about: DeepIntent
Sep 10, 2026, 09:00 ET NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE
development of a strategy to generate a series of impactful publications following analysis of clinical data and exploration of the effects of the study drug beyond the initial study objective, as well as on subsets of the population. The ability to leverage our important VALTOCO clinical study data using
More news about: Neurelis, Inc.
Sep 10, 2026, 09:00 ET Prime Therapeutics names Manmohan Mahajan chief financial officer
support to customers and members. Prime provides care to millions of people across the country through pharmacy benefit management, specialty and medical drug management, and state government solutions. Prime creates a new standard for the industry by doing what's right through a conflict-free approach, offering
More news about: Prime Therapeutics LLC
Sep 10, 2026, 09:00 ET Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
strategies and enable potential future diagnostic development."The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x's broader effort to explore potential future diagnostic applications
More news about: Lunit
Sep 10, 2026, 08:52 ET Drip Gym Expands Mobile Iron IV Therapy to Texas, Delivering At-Home Venofer® Infusions Across Houston, Dallas, Austin, and San Antonio
it isn't part of the standard hospital referral flow."Drip Gym's iron IV uses Venofer®, an iron sucrose formulation approved by the Food and Drug Administration. Every infusion requires a physician-reviewed complete blood count and ferritin panel from the past 90 days to protect against iron overload.
More news about: Drip Gym
Sep 10, 2026, 08:49 ET GBI Bio Appoints Jesse McCool, Ph.D., as Chief Executive Officer
programs, 50 bioconjugation projects, and 50 regulatory filings. Its integrated, single-site operations encompass process development, cGMP drug substance and drug product manufacturing. As a proven turnkey CDMO partner, GBI combines scientific and quality rigor with a strong customer-centric culture to
More news about: GBI Biomanufacturing
Sep 10, 2026, 08:10 ET Consano Bio Announces Peer-Reviewed Publication Supporting the Therapeutic Potential of C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
supraphysiologic concentrations of these proteins directly to the site of nerve injury. C-1101 has received Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in a Phase 1 clinical trial.About Consano BioConsano Bio is a clinical-stage
More news about: Consano Bio
Sep 10, 2026, 08:00 ET Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable
More news about: Lipocine Inc.
Sep 10, 2026, 08:00 ET Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
healthcare providers to deliver high-quality care for patients receiving COMP360 psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA).
More news about: Fluence International, Inc.
Sep 10, 2026, 08:00 ET Dimer Health Brings the Hospital "Call Button" Home with AiME
AiME helps by explaining medications, running a reconciliation check, and flagging potential discrepancies — like duplicate medications or the same drug listed at two different doses — for a clinician to confirm. When something needs a human judgement call, AiME escalates directly to Dimer's Transitionist
More news about: Dimer Health
Sep 10, 2026, 07:53 ET Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury
will enable Vincere to complete key IND-enabling safety studies required to advance its kidney-focused USP30 inhibitor toward an Investigational New Drug (IND) application and first-in-human clinical development.Targeting Mitochondrial Dysfunction to Promote Kidney RecoveryMitochondrial
More news about: Vincere Biosciences
Sep 10, 2026, 07:30 ET TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
against acute bacterial skin and skin structure infections (ABSSSI).The U.S. Food and Drug Administration has granted TNP-2092 Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations for the treatment of PJI. Additionally, TNP-2092 received the Excellence Award at
More news about: TenNor Therapeutics (Suzhou) Limited
Sep 10, 2026, 07:00 ET Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.Media
More news about: Armata Pharmaceuticals, Inc.
Sep 10, 2026, 07:00 ET Health Canada Clears Updated Clinical Trial Protocol for Redsenol-1 Plus
NCI Drug Dictionary of the U.S. National Cancer Institute (NCI). Ginsenosides have attracted scientific interest because of their diverse biological activities."Cancer-related
More news about: Canada Royal Enoch Phytomedicine Ltd.
Sep 10, 2026, 07:00 ET Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp Holdings Inc
Sep 10, 2026, 05:37 ET Full-Life Technologies annonce l'obtention de l'autorisation IND de la FDA et de l'autorisation réglementaire australienne pour l'essai clinique de phase 1 sur le [²²⁵Ac]Ac-FL-261
base d'actinium et en phase clinique, a annoncé aujourd'hui que la Food and Drug Administration (« FDA ») a approuvé la demande de la Société relative à un nouveau médicament expérimental (« IND » - Investigational New Drug) de la Société concernant le [225Ac]Ac-FL-261 et que le programme
More news about: Full-Life Technologies
Sep 10, 2026, 03:26 ET /C O R R E C T I O N -- CordenPharma/
company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules,
More news about: CordenPharma
Sep 10, 2026, 02:48 ET /C O R R E C T I O N -- CordenPharma/
company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules,
More news about: CordenPharma
Sep 10, 2026, 01:47 ET Full-Life Technologies kondigt IND-goedkeuring van de Amerikaanse FDA en goedkeuring van de Australische regelgevende instanties aan voor klinische fase 1-studie naar [²²⁵Ac]Ac-FL-261
geïntegreerd, wereldwijd opererend radiofarmaceutisch bedrijf op basis van actinium in klinisch stadium, heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration ("FDA") de aanvraag van het bedrijf voor onderzoek naar een nieuw geneesmiddel ("IND") voor [225Ac]Ac-FL-261 heeft goedgekeurd
More news about: Full-Life Technologies
Sep 09, 2026, 23:31 ET EMPE Diagnostics to Unveil CircuLOK Product Range at NATCON 2026, Expanding Access to TB Drug-Resistance Diagnostics
to select the resistance coverage they need, scale testing to demand, and deploy tests across the diagnostic network. The CircuLOK range for drug resistance testing is built around flexibility: laboratories can select the resistance panel that matches their patient population and budget, and expand
More news about: EMPE Diagnostics AB